PRVs Revisited During Drug Pricing Hearing: FDA Still Doesn’t Like Them
This article was originally published in RPM Report
Executive Summary
It’s not what most people will remember from the event, but the Feb. 4 hearing on drug pricing included an exchange reinforcing FDA’s reservations about the priority review voucher program – including a quote from an interview published by The RPM Report.